PURPLE BIOTECH LTD.

News

Purple Biotech to Present New Preclinical Data of IM1240 at the European Association for Cancer Research (EACR) 2026 Annual Congress which takes place June 8-11, 2026 in Budapest, Hungary.
Jun 16, 2026Purple Biotech
The post Purple Biotech to Present New Preclinical Data of IM1240 at the European Association for Cancer Research (EACR) 2026 Annual Congress which takes place June 8-11, 2026 in Budapest, Hungary. appeared first on Purple Biotech.
Toxicology study results in NHP validated improved PK and safety profile of CAPTN-3 masking design, revealing an extended therapeutic window
Jun 11, 2026Purple Biotech
Presented at the EACR 2026 Congress, June, 2026 The post Toxicology study results in NHP validated improved PK and safety profile of CAPTN-3 masking design, revealing an extended therapeutic window appeared first on Purple Biotech.
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress which takes place December 10-12, 2025 in London, UK.
Dec 22, 2025Purple Biotech
The post Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress which takes place December 10-12, 2025 in London, UK. appeared first on Purple Biotech.
CAPTN-3 unique design demonstrated by 2 novel platform trispecific T Cell engagers
Dec 11, 2025Purple Biotech
Presented at the ESMO Immuno-Oncology Congress 2025, December, 2025 The post CAPTN-3 unique design demonstrated by 2 novel platform trispecific T Cell engagers appeared first on Purple Biotech.
Purple Biotech will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025.
Aug 27, 2025Purple Biotech
The post Purple Biotech will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025. appeared first on Purple Biotech.
CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers
Jun 23, 2025Purple Biotech
Presented at the EACR 2025 Congress, June, 2025 The post CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers appeared first on Purple Biotech.
Final results of the randomized Phase 2 of CM24 in pancreatic cancer: Improved outcomes and significant efficacy in a serum biomarker-enriched subgroup
May 1, 2025Purple Biotech
Presented at the AACR annual meeting, April 2025 The post Final results of the randomized Phase 2 of CM24 in pancreatic cancer: Improved outcomes and significant efficacy in a serum biomarker-enriched subgroup appeared first on Purple Biotech.
APC-loss as a potential biomarker for NT219 treatment in colorectal cancer
Apr 29, 2025Purple Biotech
Presented at the AACR annual meeting, April 2025 The post APC-loss as a potential biomarker for NT219 treatment in colorectal cancer appeared first on Purple Biotech.
NT219 overcomes immune evasion mechanisms in head and neck squamous cell carcinoma (HNSCC)
Apr 29, 2025Purple Biotech
Presented at the AACR annual meeting, April 2025 The post NT219 overcomes immune evasion mechanisms in head and neck squamous cell carcinoma (HNSCC) appeared first on Purple Biotech.
Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
Apr 2, 2025Purple Biotech
The post Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025 appeared first on Purple Biotech.